What is the appropriate dosing regimen for testosterone cypionate in women, including starting dose, titration schedule, target serum testosterone range, and monitoring parameters?

Testosterone Cypionate Dosing for Women

There are no established evidence-based guidelines for testosterone cypionate dosing in women, and current clinical practice guidelines explicitly recommend against routine testosterone therapy in women except for postmenopausal women with hypoactive sexual desire disorder (HSDD)—for which transdermal preparations, not injectable cypionate, are the evidence-based choice.

Critical Context: Lack of Guideline Support

The available guidelines address testosterone therapy exclusively in men 1, 2, 1 or specifically recommend against generalized testosterone use in women 3. The 2014 Endocrine Society guideline on androgen therapy in women explicitly states:

• We recommend against making a clinical diagnosis of androgen deficiency syndrome in healthy women due to lack of a well-defined syndrome 3
• We suggest against treatment with testosterone preparations formulated for men due to lack of data on efficacy and safety in women 3
• We recommend against routine testosterone treatment in women with low androgen levels from various causes 3

The 2019 Global Consensus Statement identifies only one evidence-based indication: postmenopausal women with HSDD, and specifically recommends transdermal preparations to achieve physiologic premenopausal female testosterone ranges 4.

Off-Label Use: When Testosterone Cypionate Is Prescribed

Despite guideline recommendations, testosterone cypionate is used off-label in clinical practice, particularly for:

• Female-to-male (FTM) transgender patients seeking masculinization
• Postmenopausal women with refractory HSDD when approved formulations are unavailable

Dosing Regimens from Clinical Practice

For FTM transgender patients (the only population with substantial published dosing data):

Starting dose: 50 mg weekly subcutaneously or intramuscularly 5, 6, 7

Titration approach:

• Initial dose: 50 mg weekly
• Assess testosterone levels at 3-6 weeks 3, 4
• Adjust dose to achieve male physiologic range (300-700 ng/dL) 5, 6
• Typical maintenance range: 50-150 mg weekly (median 75-80 mg) 5
• Alternative: 100-200 mg every 2 weeks 8, though weekly dosing provides more stable levels 9

Route considerations:

• Subcutaneous administration is equally effective as intramuscular and strongly preferred by patients (20/22 patients in one study marked preference for SC) 5
• SC injections are less painful, easier to self-administer, and achieve stable therapeutic levels 5, 7, 9

Target Testosterone Levels

For masculinization (FTM patients): Mid-normal male range (400-700 ng/dL) 5, 6

For women seeking feminizing doses (theoretical, based on consensus recommendations): Physiologic premenopausal female range (approximately 15-70 ng/dL total testosterone) 4—however, achieving this with injectable cypionate is impractical and not recommended 3, 4.

Monitoring Parameters

If testosterone cypionate is prescribed off-label to women:

Baseline:

• Total testosterone level 3, 4
• Hematocrit 1
• Lipid panel
• Liver function tests 10

Follow-up:

• Testosterone level at 3-6 weeks after initiation 3, 4
• Testosterone level every 6 months thereafter to screen for overuse 3, 4
• Timing of blood draw: Midway between injections for cypionate 1
• Hematocrit every 3-6 months initially, then annually 1
• Clinical assessment for signs of androgen excess: acne, hirsutism, voice deepening, clitoromegaly 3, 4

Stop therapy if:

• No clinical benefit by 6 months 4
• Signs of androgen excess develop
• Hematocrit >50% (relative contraindication) 1

Critical Pitfalls

1. Supraphysiologic dosing: Injectable testosterone preparations formulated for men (200 mg/mL) make it extremely difficult to achieve physiologic female testosterone levels. The consensus explicitly recommends against preparations that result in supraphysiologic concentrations, including injections 4.

2. Lack of FDA approval: No testosterone preparation is FDA-approved for women in the United States 3, 8. Off-label use carries medicolegal considerations.

3. Compounded preparations: Cannot be recommended due to lack of quality control, unless no approved alternative exists 4.

4. Monitoring without context: Testosterone levels must be interpreted based on timing relative to injection. Midpoint levels for cypionate are most informative 1.

5. Inappropriate indications: Testosterone should not be used for infertility, cognitive dysfunction, cardiovascular health, bone health, or general well-being in women 3.

Practical Algorithm for Clinical Decision-Making

Step 1: Confirm indication

• Is this a postmenopausal woman with formally diagnosed HSDD after biopsychosocial assessment? 4
• If yes → First-line: transdermal testosterone preparation (patch, gel) if available 4
• If no approved female formulation available → Consider off-label male formulation with extreme caution 4

Step 2: If proceeding with testosterone cypionate (off-label)

• Obtain baseline testosterone, hematocrit, lipids, LFTs
• Start 50 mg weekly SC (easier for self-administration) 5, 7
• Target physiologic female range if treating HSDD; male range if masculinizing

Step 3: Monitor and titrate

• Check testosterone at 3-6 weeks (midway between injections)
• Adjust dose by 25 mg increments
• Reassess every 6 months
• Discontinue if no benefit by 6 months 4

The evidence strongly favors transdermal preparations over injectable testosterone cypionate for women when testosterone therapy is indicated. Injectable cypionate should be reserved for situations where approved female formulations are genuinely unavailable and the indication is compelling (primarily HSDD in postmenopausal women or gender-affirming care).